Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00120125
Entity page: /trial/NCT02446600 ↗
Edges: 20

Neighbours: 13 cancers6 drugs
Drawn: 19 of 19 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer condition of …CONDITION_OFderived13 of 13
← condition of	Fallopian Tube Carcinoma registry condition “Recurrent Fallopian Tube Carcinoma” mapped CURATED_BROADER	—	—	Fallopian Tube Carcinoma	1	Observed	clinicaltrials	graph →
← condition of	Fallopian Tube Clear Cell Adenocarcinoma

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer intervention of …INTERVENTION_OFderived7 of 7
← intervention of	Carboplatinsmall molecule registry intervention “Carboplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Cediranibsmall molecule registry intervention “Cediranib Maleate” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Doxorubicinsmall molecule registry intervention “Pegylated Liposomal Doxorubicin Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine Hydrochloride” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Gemcitabinesmall molecule registry intervention “Gemcitabine” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Olaparibsmall molecule registry intervention “Olaparib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Paclitaxelsmall molecule registry intervention “Paclitaxel” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer intervention of …INTERVENTION_OFderived7 of 7

← intervention of

Carboplatinsmall molecule

registry intervention “Carboplatin” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Cediranibsmall molecule

registry intervention “Cediranib Maleate” (DRUG) mapped ALIAS

—